Go to content
UR Home

Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial

Heidemann, E. ; Stoeger, H. ; Souchon, R. ; Hirschmann, W.-D. ; Bodenstein, H. ; Oberhoff, C. ; Fischer, J. T. ; Schulze, M. ; Clemens, M. ; Andreesen, Reinhard ; Mahlke, M. ; König, M. ; Scharl, A. ; Fehnle, K. ; Kaufmann, M.


BACKGROUND: To determine whether patients with high-risk metastatic breast cancer draw benefit from combination chemotherapy as first-line treatment. PATIENTS AND METHODS: A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons